17β-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor
© Hamelers et al; licensee BioMed Central Ltd. 2003
Received: 28 January 2003
Accepted: 11 July 2003
Published: 11 July 2003
Human MCF-7 cells have been studied extensively as a model for breast cancer cell growth. Many reports have established that serum-starved MCF-7 cells can be induced to proliferate upon the sole addition of 17β-estradiol (E2). However, the extent of the mitogenic response to E2 varies in different MCF-7 strains and may even be absent. In this study we compared the E2-sensitivity of three MCF-7 laboratory strains.
The MCF-7S line is non-responsive to E2, the MCF-7 ATCC has an intermediate response to E2, while the MCF-7 NKI is highly E2-sensitive, although the levels and activities of the estrogen receptor (ER) are not significantly different. Both suramin and IGF type I receptor blocking antibodies are able to inhibit the mitogenic response to E2-treatment in MCF-7 ATCC and MCF-7 NKI cells. From this we conclude that E2-induced proliferation is dependent on IGF type I receptor activation in all three MCF-7 strains.
The results presented in this article suggest that E2-responsiveness of MCF-7 cells is dependent on the secretion of an autocrine factor activating the IGF-IR. All three strains of MCF-7 breast cancer cells investigated do not respond to E2 if the IGF-RI-pathway is blocked. Generally, breast cancer therapy is targeted at inhibiting estrogen action. This study suggests that inhibition of IGF-action in combination with anti-estrogen-treatment may provide a more effective way in treatment or even prevention of breast cancer.
Clinical studies have shown that therapeutic agents preventing the synthesis and actions of estrogens are highly successful in the treatment of breast cancer. The mechanisms by which estrogens stimulate cell proliferation, however, are still not clear. The epithelial breast cancer derived MCF-7 cell line is one of the most frequently used model systems. Many groups have reported that addition of E2 to the medium of these cells induces a proliferative response [1–5]. However, a comparison of different laboratory strains of MCF-7 reveals that the degree of stimulation differs, and may even be absent [6–9].
Recently, we have demonstrated that E2 does not induce cell proliferation in the MCF-7S cell line under serum-free, steroid hormone-free conditions. However, E2 in synergism with submitogenic concentrations of insulin-like growth factor I (IGF-I; 2 ng/ml) does induce a proliferative response, comparable to the response to mitogenic amounts of IGF-I (20 ng/ml) . We have found that both E2 and mitogenic amounts of IGF-I strongly induce cyclin D1 expression, whereas submitogenic amounts of IGF-I do not significantly elevate cyclin D1 levels. IGF-I, but not E2, is able to activate PI3-kinase, which leads to inhibition of GSK3β activity. Here, a per se non-mitogenic amount of IGF-I suffices. Inhibition of GSK3β triggers nuclear accumulation of the cyclin D1, but only if cyclin D1 levels are strongly induced concomitantly, which is effectuated by E2. After cyclin D1 accumulates in the nucleus, activation of the cyclin D1/CDK4 complex and subsequent cell cycle progression is observed .
In contrast to other laboratory MCF-7 strains, MCF-7S cells are almost completely growth arrested in G0/G1 phase of the cell cycle by serum deprivation in estrogen-free medium, without the need for estrogen antagonists or other inhibitors to reach quiescence. Other laboratory strains of MCF-7 proliferate well when E2 is added after serum-deprivation. In the present study, we compare three distinct MCF-7 strains to determine the cause of their differences in sensitivity for E2. The MCF-7S cell line is non-responsive to E2. The MCF-7 cell line from the American Type Culture Collection (referred to as "MCF-7 ATCC") shows an intermediate E2-response. The MCF-7 line obtained from the Dutch Cancer Institute in Amsterdam, The Netherlands (referred to as "MCF-7 NKI") is highly E2-responsive.
Three MCF-7 strains exhibit differences in E2-responsiveness
The three MCF-7 strains express ERα and show E2-responsive cyclin D1 gene expression
In order to detect differences in functionality of the ER, we analyzed the expression level of an E2-responsive gene, cyclin D1, in untreated serum-starved and in E2-treated cells. Like in MCF-7S cells, E2 treatment induces a strong increase in cyclin D1 levels in both MCF-7 ATCC and MCF-7 NKI cells. No significant differences in cyclin D1 induction were observed in the three MCF-7 strains (figure 2B). Taken together, these results indicate that the differences in growth response upon E2 treatment of the MCF-7 strains are not caused by their ER expression level or functionality.
Suramin inhibits the E2-induced cell cycle progression in E2-responsive MCF-7 cells
To investigate whether E2 can induce cell cycle progression in MCF-7 ATCC and NKI cells without subsequent activation of the IGF type I receptor, a DNA synthesis assay was performed in which 200 μg/ml suramin was added to the cells one hour prior to stimulation with IGF-I, E2 or the combination of both hormones. Suramin is an anti-tumor agent inhibiting the proliferation of a variety of human cancer cell lines cultured in vitro [12–15]. Suramin acts extracellularly by interfering with the binding of growth factors to their receptors , including several which are known to be involved in tumor growth or development, like IGF-I , and TGFβ .
Blocking IGF-RI with αIR3 antibody inhibits E2-induced cell cycle progression in E2-responsive MCF-7 cells
The observed inhibition of DNA synthesis theoretically might be due to toxicity of the antibodies added to the cells. To exclude this possibility, the specificity of inhibition was examined by determining whether other signaling pathways are still intact in antibody treated cells. To this end, the TPA-induced synthesis of the CKI p21cip1/waf1 protein was studied on Western blot. TPA induces the synthesis of p21cip1/waf1 via activation of the ERK pathway independent of IGF-RI . A moderate elevation of p21cip1/waf1 levels is also observed when MCF-7 cells are treated with mitogenic amounts of IGF-I .
MCF-7 ATCC and MCF-7 NKI cells secrete a factor that makes them more sensitive to E2-treatment
In view of the fact that activation of the IGF-RI is important for E2-induced cell cycle progression in MCF-7 ATCC and MCF-7 NKI cells, we investigated the possibility of autocrine stimulation of the IGF-RI in these MCF-7 strains. To this end, we studied the effect of conditioned media on the E2-responsiveness of the MCF-7 strains in a DNA-synthesis assay. MCF-7S, ATCC and NKI cells were seeded in 162 cm2 culture flasks and incubated in serum-free, estrogen-free medium for two days, after which the conditioned media were collected. For the DNA-synthesis assay, MCF-7S, MCF-7 ATCC and MCF-7 NKI cells were seeded in 24 wells plates, and serum-starved for 24 h. Prior to stimulation the serum-free medium on the three MCF-7 strains was replaced by the conditioned media, or by fresh serum-free medium as a control. After 15 minutes, no mitogens, IGF-I (2 or 20 ng/ml), 1 nM E2 or the combination of 1 nM E2 and 2 ng/ml IGF-I were added to the media. 24 h later, 3H-TdR was added for a 6 h period, after which the cells were harvested.
Also in the MCF-7 ATCC cell line, the conditioned media from MCF-7 ATCC and MCF-7 NKI, but not the conditioned medium of MCF-7S, induce additional 3H-TdR incorporation in cells treated with E2 when compared to cells incubated in fresh serum-free medium with E2. In MCF-7 ATCC, incubation in the conditioned media from the two E2-inducible cell lines leads to a higher incorporation in untreated and in IGF-I (2 ng/ml) treated cells. This increase is less pronounced in the MCF-7S cell line (figure 6).
In MCF-7 NKI cells, the conditioned media have no significant effect on the amount of incorporation induced by E2, but they do stimulate 3H-TdR incorporation in untreated and in IGF-I (2 ng/ml) stimulated cells (figure 6). These results suggest that the MCF-7 ATCC and MCF-7 NKI cells secrete a factor into the medium that activates the IGF-RI and synergizes with E2 to induce cell cycle progression in all three strains of MCF-7.
MCF-7S cells do not proliferate upon addition of only E2 (1 nM) to serum-free medium. Other strains of MCF-7, here indicated as MCF-7 ATCC and MCF-7 NKI, which were tested under identical conditions as MCF-7S, do respond to E2-treatment. We have shown that that the observed differences in growth response upon E2-treatment of the MCF-7 strains are not caused by differences in ER expression level or functionality.
The effect of E2 on the incorporation of 3H-TdR is completely inhibited by suramin-preincubation in all three cell lines to levels lower than background incorporation in untreated cells. More specifically, we have shown that the induction of DNA-synthesis by E2 in all three cell lines could be blocked completely by incubating the cells with 1 μg/ml of αIR3 antibody, which binds to the IGF-RI and thereby inhibits the binding of ligand. From this we conclude that E2-induced DNA synthesis in MCF-7 cells is dependent on IGF-RI signaling.
Our results indicate that the E2-responsive strains, MCF-7 ATCC and MCF-7 NKI, autonomously activate their IGF-IR, and that this activation is required for their response to E2. Since endogenous production of growth factors is a common feature of many tumor cells, we investigated whether the two E2-responsive MCF-7 strains secrete an autocrine factor capable of activating their IGF-RI. We demonstrated that E2-insensitive cells become E2-sensitive when challenged with conditioned medium of E2-sensitive cells. This suggests that E2-sensitive cells secrete an autocrine factor capable of activating the IGF-RI.
Differences in the levels of production of IGF-IR agonists by the breast cancer cells may explain the differences observed in the E2-sensitivity of the three MCF-7 strains. Van der Burg et al., using a sensitive bioassay, could not detect any IGF-I or -II production in MCF-7S cells . Other reports indicate expression of IGFs by certain MCF-7 strains. The majority of reports studying this issue report the absence of detectable IGF-I expression in MCF-7 [22, 23]. Expression of IGF-II mRNA has been detected by Northern blot analysis and RNase protection assays [24, 25]. After removal of the binding proteins, concentrations between 4.7 and 14.4 ng/ml per 107 MCF-7 cells of IGF-II protein has been found in conditioned medium depending on the technique used (RIA and radioreceptor assays) . Significantly, Yee et al. observed that IGF-II expression by MCF-7 cells increases with the passage number of the cell culture . This observation suggests that the factor secreted by E2-sensitive cells may be IGF-II. IGF-II has been shown to induce a mitogenic response in a variety of breast cancer cell lines. It has been found to be slightly less potent than IGF-I, since 2–4 times higher concentrations IGF-II are needed for equal responses in a DNA synthesis assay [25, 26]. Even so, the concentrations reportedly present in the conditioned medium of MCF-7 cells  are sufficient to synergistically induce a mitogenic response in MCF-7 cells upon addition of E2. The reason for the change in IGF-II expression over time is not clear. The MCF-7 cell line was isolated from a pleural effusion derived from a breast carcinoma , and was shown to consist of several different subpopulations of cells . It is plausible that during cultivation of the initially heterogeneous cell line an IGF-II-expressing cell type is naturally selected because of its growth advantage over non-growth-factor expressing cells.
MCF-7S cells, in contrast to other laboratory MCF-7 strains, are almost completely growth arrested in G0/G1 phase of the cell cycle by serum deprivation in estrogen-free medium, without the need for estrogen antagonists or other inhibitors to reach quiescence. We have found that the MCF-7S cells show this characteristic for about 25 to 30 passages, after which the cells start to grow more rapidly and do no longer show complete growth arrest upon serum withdrawal. Furthermore, during cell culture the cells become more IGF independent and significant proliferation can be induced by the sole addition of E2 to the serum-free medium. Endogenous expression of IGF-I or IGF-II by E2-sensitive MCF-7 strains could account for their observed E2 inducible growth, independent of IGF-I addition. The change in E2-responsiveness of MCF-7S may indicate that prolonged growth in tissue culture triggers the production of IGF. Alternatively, IGF-producing cells that were already present in the original culture gain a growth advantage and gradually overgrow the non-IGF-producing cells. In conclusion, the differential response of different MCF-7 strains to E2 and IGF-I may well be due to differences in the individual IGF-expression status in these strains. Using RT-PCR, we found than none of the MCF-7 strains produce IGF-I. However, in all three of the cell lines IGF-II mRNA could be detected (data not shown). Thus, IGF-II may well be the autocrine factor involved in regulation of the response to E2.
In conclusion, we have shown that E2-responsiveness of MCF-7 cells is dependent on the secretion of an autocrine factor activating the IGF-IR. All three strains of MCF-7 breast cancer cells investigated do not respond to E2 if the IGF-RI-pathway is blocked. Generally, breast cancer therapy is targeted at inhibiting estrogen action. This study suggests that inhibition of IGF-action in combination with anti-estrogen-treatment may provide a more effective way in treatment or even prevention of breast cancer.
Anti-p21CIP1/WAF1 (H-164) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). IGF-I was from GroPep (Adelaide, Australia). Aprotinin, E2, sodium selenite, suramin, and TPA were purchased from Sigma (St. Louis, MO). Albumin, bovine fraction V (BSA, Catalogue number 840533), Na3VO4 and transferrin were from ICN Biomedicals, Inc. (Aurora, OH). The αIR3 antibody was a kind gift of Dr. S. van Buul-Offers from the Department of Pediatric Endocrinology, UMC Utrecht, The Netherlands.
The MCF-7 human breast cancer cell lines were cultured in Dulbecco's Minimal Essential Medium/Ham's F12 medium (1:1), supplemented with 10% fetal calf serum, 300 μg/ml of glutamine, 100 IU/ml of penicillin and 100 μg/ml of streptomycin. Cell cultures of 40–60% confluence were used for experiments. Prior to experiments, MCF-7 cells were cultured for 24 h in phenol red-free medium containing 5% dextran-coated charcoal-treated serum, followed by an incubation in phenol red-free, serum-free medium, supplemented with 0.2% bovine serum albumin (BSA), 10 μg/ml of transferrin and 30 nM sodium selenite for at least 24 h.
Assays were performed in 24-well plates. Serum-starved cells were stimulated with IGF-I, E2, or a combination of the two and after 24 h of incubation 3H-labeled thymidine (2 μCi/ml) was added. 30 h after the addition of the stimuli, cells were fixed with 10% trichloroacetic acid, washed in PBS and lysed in 0.1 M NaOH, followed by liquid scintillation counting.
Experiments were performed in 6-well plates. After stimulation, cells were washed with ice-cold PBS and lysed in lysis buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol). Lysates were boiled for 5 min and protein concentrations were determined using the BCA protein assay (Pierce, Rockford, IL). After addition of 0.1% bromophenol blue and 5% β-mercaptoethanol to the samples, equal amounts of protein (5–50 μg) were size-separated on a SDS-polyacrylamide gel and transferred to nitrocellulose. The membrane was stained with Ponceau S (Sigma) to check for equal loading and blocked with 2–3% non-fat milk or 0.5–2% BSA in TBST (150 mM NaCl, 10 mM Tris-HCl pH 8.0, 0.2% Tween 20) for 1 h. Incubation with the primary antibody was performed overnight at 4°C in 0.1 × blocking solution. The membrane was washed in TBST and exposed to horseradish peroxidase-coupled secondary antibody for 1 h in TBST. For detection the Western Blot Chemiluminescence Reagent Plus system (NEN Life Science Products Inc., Boston, MA) was used.
insulin-like growth factor
IGF binding protein
insulin-like growth factor type I receptor
Michigan Cancer Foundation 7 cell line, derived from an epithelial breast cancer
12-O-tetradecanoyl phorbol 13-acetate
We would like to thank Dr. S van Buul-Offers for the kind gift of αIR3 anti-IGF-RI antibody, and B. Hendriks-Stegeman and Dr. M. Jansen for helpful discussions. This work was supported by the Dutch Cancer Foundation, KWF, Grant UU 98-1701.
- Dupont J, Le Roith D: Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol. 2001, 54: 149-154. 10.1136/mp.54.3.149.PubMed CentralView ArticlePubMedGoogle Scholar
- Lai A, Sarcevic B, Prall OW, Sutherland RL: Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). J Biol Chem. 2001, 276: 25823-25833. 10.1074/jbc.M100925200.View ArticlePubMedGoogle Scholar
- Keshamouni VG, Mattingly RR, Reddy KB: Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells: A role for HER2 and PKC-delta. J Biol Chem. 2002, 277: 22558-22565. 10.1074/jbc.M202351200.View ArticlePubMedGoogle Scholar
- Castoria G, Barone MV, Di Domenico M, Bilancio A, Ametrano D, Migliaccio A: Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J. 1999, 18: 2500-2510. 10.1093/emboj/18.9.2500.PubMed CentralView ArticlePubMedGoogle Scholar
- Ahmad S, Singh N, Glazer RI: Role of AKT1 in 17β-estradiol- and insulin-like growth factor I (IGE-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol. 1999, 58: 425-430. 10.1016/S0006-2952(99)00125-2.View ArticlePubMedGoogle Scholar
- Edwards DP, McGuire WL: Estrogen action in human breast cancer. Anticancer Res. 1982, 2: 297-308.PubMedGoogle Scholar
- Jozan S, Moure C, Gillois M, Bayard F: Effects of estrone on cell proliferation of a human breast cancer (MCF-7) in long term tissue culture. J Steroid Biochem. 1979, 10: 341-342. 10.1016/0022-4731(79)90263-2.View ArticlePubMedGoogle Scholar
- Shafie SM: Estrogen and the growth of breast cancer: new evidence suggests indirect action. Science. 1980, 209: 701-702.View ArticlePubMedGoogle Scholar
- Van der Burg B, Rutteman GR, Blankenstein MA, De Laat SW, Van Zoelen EJJ: Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen. J Cell Physiol. 1988, 134: 101-108.View ArticlePubMedGoogle Scholar
- Hamelers IHL, van Schaik RFMA, van Teeffelen HAAM, Sussenbach JS, Steenbergh PH: Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells. Exp Cell Res. 2002, 273: 107-117. 10.1006/excr.2001.5430.View ArticlePubMedGoogle Scholar
- Hamelers IHL, van Schaik RFMA, Sipkema J, Sussenbach JS, Steenbergh PH: Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells. J Biol Chem. 2002, 277: 47645-47652. 10.1074/jbc.M208727200.View ArticlePubMedGoogle Scholar
- Berns EM, Schuurmans AL, Bolt J, Lamb DJ, Foekens JA, Mulder E: Antiproliferative effects of suramin on androgen responsive tumour cells. Eur J Cancer. 1990, 26: 470-474.View ArticlePubMedGoogle Scholar
- La Rocca RV, Danesi R, Cooper MR, Jamis-Dow CA, Ewing MW, Linehan WM: Effect of suramin on human prostate cancer cells in vitro. J Urol. 1991, 145: 393-398.PubMedGoogle Scholar
- Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F, Myers CE: Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer. 1992, 28A: 864-866.View ArticlePubMedGoogle Scholar
- Vignon F, Prebois C, Rochefort H: Inhibition of breast cancer growth by suramin. J Natl Cancer Inst. 1992, 84: 38-42.View ArticlePubMedGoogle Scholar
- Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE: Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989, 7: 499-508.PubMedGoogle Scholar
- Ravera F, Miglietta L, Pirani P, Ferrini S, Favoni RE: Suramin-induced growth inhibition and insulin-like growth factor-I binding blockade in human breast carcinoma cell lines: potentially related events. Eur J Cancer. 1993, 29A: 225-230.View ArticlePubMedGoogle Scholar
- Wade TP, Kasid A, Stein CA, LaRocca RV, Sargent ER, Gomella LG: Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. J Surg Res. 1992, 53: 195-198.View ArticlePubMedGoogle Scholar
- de Vente JE, Kukoly CA, Bryant WO, Posekany KJ, Chen J, Fletcher DJ: Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd45 in initiating death. J Clin Invest. 1995, 96: 1874-1886.PubMed CentralView ArticlePubMedGoogle Scholar
- Dufourny B, Alblas J, Van Teeffelen HAAM, Van Schaik FMA, Van der Burg B, Steenbergh PH: Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem. 1997, 272: 31163-31171. 10.1074/jbc.272.49.31163.View ArticlePubMedGoogle Scholar
- Van der Burg B, Isbrucker L, Selm-Miltenburg AJ, De Laat SW, Van Zoelen EJ: Role of estrogen-induced insulin-like growth factors in the proliferation of human breast cancer cells. Cancer Res. 1990, 50: 7770-7774.PubMedGoogle Scholar
- Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ: Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989, 3: 509-517.View ArticlePubMedGoogle Scholar
- Gebauer G, Jäger W, Lang N: mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells. Anticancer Res. 1998, 18: 1191-1195.PubMedGoogle Scholar
- Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schwartz A: Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res. 1988, 48: 6691-6696.PubMedGoogle Scholar
- Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SA, Ramasharma K: Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol. 1989, 3: 1701-1709.View ArticlePubMedGoogle Scholar
- Arteaga CL, Osborne CK: Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989, 49: 6237-6241.PubMedGoogle Scholar
- Soule HD, Vazguez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973, 51: 1409-1416.PubMedGoogle Scholar
- Resnicoff M, Medrano EE, Podhajcer OL, Bravo AI, Bover L, Mordoh J: Subpopulations of MCF7 cells separated by Percoll gradient centrifugation: a model to analyze the heterogeneity of human breast cancer. Proc Natl Acad Sci U S A. 1987, 84: 7295-7299.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.